A Clinical Trial of Atezolizumab in Patients with Renal Cell Carcinoma that is at High Risk of Coming Back After Surgery (IMmotion010)

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Cancer
Renal Cell Cancer (RCC)
Renal Cell Carcinoma

Results
Download

Study results

LPS WO39210 IMmotion010 Final Results September 2022 English (PDF, 0.7 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Clinical Trial of Atezolizumab in Patients with Renal Cell Carcinoma that is at High Risk of Coming Back After Surgery (IMmotion010)

Study results

LPS WO39210 IMmotion010 Final Results September 2022 English (PDF, 0.7 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

A Clinical Trial of Atezolizumab in Patients with Renal Cell Carcinoma that is at High Risk of Coming Back After Surgery (IMmotion010)

For the latest version of this information please go to www.forpatients.roche.com